Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HTL0039732,Atezolizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Sosei Heptares
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.
Brand Name : HTL0039732
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
Lead Product(s) : HTL0039732,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Sosei Heptares
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : AST-VAC2
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Lineage Cell Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AST-VAC2 is an allogeneic, or non-patient specific, cancer vaccine candidate designed to stimulate patient immune responses to telomerase which is commonly expressed in cancerous cells but not in normal adult cells.
Brand Name : AST-VAC2
Molecule Type : Vaccine
Upfront Cash : Not Applicable
July 24, 2023
Lead Product(s) : AST-VAC2
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Lineage Cell Therapeutics
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : HTL0039732
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the Clinical Trial and Licence Agreement (CTLA), Cancer Research UK’s Centre for Drug Development will sponsor, design and execute a Phase I/IIa clinical trial of HTL00397322, a novel selective EP4 antagonist.
Brand Name : HTL0039732
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 22, 2022
Lead Product(s) : HTL0039732
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Sosei Group Corporation
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : IDE161
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Following the option exercise, IDEAYA holds exclusive worldwide license rights covering a broad class of PARG inhibitors. IDEAYA owns all commercial rights in IDE161, subject to economic obligations, worldwide license with Cancer Research UK and Universi...
Brand Name : IDE161
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 31, 2022
Lead Product(s) : IDE161
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : ALETA-001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Aleta Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Cancer Research UK’s Centre for Drug Development will fund, sponsor and conduct the first-in-human Phase 1/2a clinical trial of ALETA-001, which will be led by Dr Amit Patel’s Cellular and CAR-T therapies team at The Christie NHS Foundation Trust in ...
Brand Name : ALETA-001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 23, 2021
Lead Product(s) : ALETA-001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Aleta Biotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TT-702
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : Teon Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Cancer Research UK and Teon Therapeutics Advance New First-in-Class Cancer Drug Into Clinical Trial
Details : The partnership focuses on Teon’s potentially first-in-class small molecule adenosine A2B receptor antagonist TT-702, for the treatment of multiplecancers including prostate and triple-negative breast.
Brand Name : TT-702
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 01, 2021
Lead Product(s) : TT-702
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : Teon Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : BI-1206,Rituximab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : BioInvent
Deal Size : Undisclosed
Deal Type : Collaboration
BioInvent Streamlines Agreement on Anti-Fcγ Rll B Antibody, BI-1206, Ahead of Phase I/II Data
Details : BioInvent is conducting a Phase I/II trial of BI-1206 in combination with rituximab to treat NHL. CRUK decided to end the trial being conducted in the UK after the single-agent part of the study. Both parties have agreed to restructure their agreement co...
Brand Name : BI-1206
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 11, 2021
Lead Product(s) : BI-1206,Rituximab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : BioInvent
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : TGL-100
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Touchlight
Deal Size : Undisclosed
Deal Type : Partnership
Details : The new clinical development partnership aims at progressing a therapeutic DNA vaccine, TGL-100, into an early phase clinical trial targeting head and neck squamous cell carcinoma (HNSCC).
Brand Name : TGL-100
Molecule Type : Vaccine
Upfront Cash : Undisclosed
July 29, 2020
Lead Product(s) : TGL-100
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Touchlight
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration
Details : The expanded research collaboration will evaluate IDEAYA's PARG inhibitors in vitro in multiple ovarian cancer cell lines and in vivo in ovarian cancer xenograft models.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 11, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Ideaya Biosciences
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?